J&J Sued Over Reflux Device
The LINX Reflux Management System, a surgically-implanted magnetic ring designed to treat gastroesophageal reflux disease (GERD), is the subject of growing litigation. According to a class-action-lawsuit resource, patients are alleging that Johnson & Johnson (through its Torax/Ethicon division) misled them about serious risks and complications tied to the device.
The device was approved by the FDA in 2012 and has been touted as a less invasive alternative to traditional anti-reflux surgery. But reports of severe adverse events — including device migration, erosion into esophageal tissue, bead separation, and failure to control reflux — have spurred lawsuits.
One lawsuit (Tilghman v. Torax / Ethicon) claims the LINX device’s manufacturing was flawed: beads became disconnected from their titanium links, causing the ring to “open” and fail. Another plaintiff alleges she needed revision surgery after the device failed roughly a year after implantation.
In addition to manufacturing defect claims, there are allegations of inadequate warnings. Plaintiffs argue Johnson & Johnson did not sufficiently inform patients or the FDA of the device’s long-term risks, including migration and erosion.
Compounding concerns, J&J recently announced it will stop selling the LINX device in markets outside the U.S. — not because of safety concerns, but due to a “commercial decision.” However, some experts warn that this move may further fuel legal scrutiny.
From a clinical perspective, independent studies have shown that LINX devices can suffer structural problems: for example, a long-term study found that bead disconnection occurred 4–5 years after implantation.
🧭 Why It Matters
-
Patients who believed LINX was a safe, long-term alternative to surgery may face serious health risks — and financial burden from revision procedures.
-
The legal actions could push Johnson & Johnson and Torax/Ethicon to compensate a large number of affected patients.
-
Courts may scrutinize whether the FDA was adequately informed of device failures, influencing future device-approval standards.
-
Healthcare providers may rethink recommending LINX if long-term safety concerns are confirmed.
-
The class-action litigation could drive reforms in how medical-device risks are disclosed and monitored post-market.
⚖️ Key Legal Outcomes
-
Lawsuits accuse J&J/Torax/Ethicon of product-liability (defective design/manufacture) and failure to warn.
-
At least one plaintiff has had to have her LINX device surgically removed due to failure.
-
The device has a known FDA Class II recall for certain manufacturing defects (bead separation).
-
J&J is withdrawing the LINX system from markets outside the U.S., which may affect how global litigation proceeds.
-
Lawyers believe there is potential for a multidistrict (or class) settlement compensating patients for revision surgeries and other damages.
